Redx Pharma PLC - Macclesfield, England-based treatments for cancer and fibrotic disease - successfully initiates dosing of the first patient cohort with a combination of RXC004, Redx's lead drug candidate and Bristol Myers Squibb Co's nivolumab, and anti-PD-1 antibody.
Redx's RXC004 is also currently being evaluated as monotherapy in a phase one clinical study, from which top line results are expected by mid-2021.
The primary objective of the phase one combination study is to evaluate the safety and tolerability of RXC004 in combination with nivolumab in patients with advanced malignancies.
The results from the combination study are expected to read out in the second half and will be used to define a dose of RXC004 to be used in combination with standard dose nivolumab in a phase two study in patients with genetically selected microsatellite stable metastatic colorectal cancer, which is planned to start to recruit patients in the second half of 2021.
Current stock price: 68.00 pence, up 6.3%
Year-to-date change: up 8.8%
By Dayo Laniyan; dayolaniyan@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
